Arformoterol
Arformoterol, Brovana (arformoterol) is a small molecule pharmaceutical. Arformoterol was first approved as Brovana on 2006-10-06. It is used to treat bronchial spasm, chronic bronchitis, and pulmonary emphysema in the USA. The pharmaceutical is active against beta-2 adrenergic receptor. In addition, it is known to target beta-1 adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Brovana (generic drugs available since 2021-06-22)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Arformoterol tartrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BROVANA | Lupin Research | N-021912 RX | 2006-10-06 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| arformoterol tartrate | ANDA | 2024-01-09 |
| arformoterol tartrate inhalation | ANDA | 2023-01-24 |
| arformoterol tartrate inhalation solution | ANDA | 2023-12-20 |
| bevespi aerosphere | New Drug Application | 2023-03-24 |
| bretzri | New Drug Application | 2020-07-23 |
| breyna | ANDA | 2020-09-24 |
| breztri | New Drug Application | 2022-01-26 |
| brovana | New Drug Application | 2023-10-04 |
| budesonide and formoterol fumarate dihydrate | NDA authorized generic | 2023-03-02 |
| duaklir pressair | New Drug Application | 2022-08-01 |
Show 5 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bronchial spasm | — | D001986 | — |
| chronic bronchitis | — | D029481 | J42 |
| pulmonary emphysema | — | D011656 | J43 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J7605 | Arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 micrograms |
Clinical
Clinical Trials
540 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | 23 | 46 | 109 | 41 | 39 | 251 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 21 | 46 | 85 | 56 | 27 | 228 |
| Emphysema | D004646 | EFO_0000464 | J43 | — | — | 4 | 4 | — | 8 |
| Disease progression | D018450 | — | — | — | — | 1 | 3 | 3 | 7 |
| Chronic bronchitis | D029481 | — | J42 | — | — | 2 | 3 | — | 5 |
| Bronchiectasis | D001987 | HP_0002110 | J47 | — | — | 1 | 2 | 1 | 4 |
| Exercise-induced asthma | D001250 | — | J45.990 | — | 1 | 1 | 1 | — | 3 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | — | 2 | 2 | 1 | — | 3 |
| Respiratory tract infections | D012141 | — | J06.9 | — | 1 | — | 1 | — | 2 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | — | 1 | — | 2 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Allergic bronchopulmonary aspergillosis | D001229 | EFO_0007140 | B44.81 | — | 4 | 4 | — | — | 4 |
| Covid-19 | D000086382 | — | U07.1 | — | 2 | 2 | — | — | 3 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | — | 1 | — | — | 1 |
| Pneumonia | D011014 | EFO_0003106 | — | — | — | 1 | — | — | 1 |
| Hypoxia | D000860 | HP_0012418 | R09.02 | — | — | 1 | — | — | 1 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | 1 | 1 | — | — | 1 |
| Smoking | D012907 | EFO_0004318 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bronchiolitis obliterans | D001989 | EFO_0007183 | — | — | 2 | — | — | — | 2 |
| Medication adherence | D055118 | EFO_0006344 | — | 2 | 2 | — | — | — | 2 |
| Interstitial lung diseases | D017563 | HP_0006530 | J84.89 | — | 1 | — | — | — | 1 |
| Cryptogenic organizing pneumonia | D018549 | EFO_1001300 | J84.116 | — | 1 | — | — | — | 1 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | — | — | — | 1 |
| Idiopathic pulmonary fibrosis | D054990 | — | J84.112 | — | 1 | — | — | — | 1 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 1 | — | — | — | 1 |
| Airway obstruction | D000402 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 6 | — | — | — | 2 | 8 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | — | — | — | — | 1 |
| Precancerous conditions | D011230 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Personal satisfaction | D010549 | — | — | — | — | — | — | 1 | 1 |
| Patient satisfaction | D017060 | — | — | — | — | — | — | 1 | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 1 | 1 |
| Bronchial hyperreactivity | D016535 | — | — | — | — | — | — | 1 | 1 |
| Hypertrophy | D006984 | EFO_0002460 | — | — | — | — | — | 1 | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Cough | D003371 | HP_0012735 | R05 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Arformoterol |
| INN | arformoterol |
| Description | N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide is a phenylethanoloamine having 4-hydroxy and 3-formamido substituents on the phenyl ring and an N-(4-methoxyphenyl)propan-2-yl substituent. It is a member of phenols, a member of formamides, a secondary amino compound, a secondary alcohol and a member of phenylethanolamines. |
| Classification | Small molecule |
| Drug class | bronchodilators (phenethylamine derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 67346-49-0 |
| RxCUI | 25255 |
| ChEMBL ID | CHEMBL1363 |
| ChEBI ID | 408174 |
| PubChem CID | 3410 |
| DrugBank | DB01274 |
| UNII ID | 5ZZ84GCW8B (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Arformoterol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,649 documents
View more details
Safety
Black-box Warning
Black-box warning for: Foradil
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,465 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use